vaayaa Inclusive Education
Healthcare risk assessment

Laboratory Technician Operations Risk Assessment: Specimen, Instrument, Data and Safety Controls

A worked example of how a clinical and research laboratory team identifies, scores and controls the risks that affect specimens, instruments, patient data, research integrity and staff safety.

Updated November 2026 8 hazards assessed Review every 6 months Highest risk: Critical to Medium
See the Laboratory Technician Operations course

Executive summary

This assessment shows how a laboratory technician team can find, rate and control the risks that matter most to patient safety, result accuracy, privacy and research integrity. Eight risks were chosen because they are plausible in everyday bench work, instrument use and data handling. Specimen mislabeling is the most serious inherent risk, while calibration drift, pipeline failure and irreproducible study methods sit at High. Each risk is scored before controls and again after existing and added controls. Most fall to Medium or Low once checks are in place, but specimen identification stays at Medium because harm to a patient remains serious. The first actions are a second identifier check, calibration and quality control records with dated review, role based access and a retention schedule. The laboratory is a teaching example, so every score illustrates method, not a real service.

Focus area
Laboratory technician operations in healthcare
Setting
Hospital or independent diagnostic laboratory with an attached research and quality function
Method
Five by five likelihood and impact risk register

Scope

This assessment covers the day to day work of laboratory technicians, from specimen receipt and testing to result release, data storage, instrument care and research use of residual samples. It does not cover clinical diagnosis or treatment decisions. Assumptions: the setting, jurisdiction, instruments and information systems are not specified, so general practice is described and specialist review is needed for any real site.

Context

The laboratory receives blood, tissue and swab specimens from wards, clinics and outside referrers. Technicians log specimens in a laboratory information system, run automated analysers, check results against quality control material and release reports to clinicians. Some residual samples are used for internal method studies and occasional approved research. Reference data is licensed from outside suppliers. Each hazard is scored before controls to show its natural level, then again after existing controls and the additional controls proposed.

Objectives, assets and stakeholders

The objective is to deliver accurate and timely results, protect patients and staff, keep specimens and data secure, use residual material only within approved purposes, and maintain trust with clinicians, patients, regulators and research partners. Assets in scope include specimens and their labels, analysers and their calibration records, the laboratory information system, quality control data, reference datasets under licence, and the reputation of the service. Stakeholders include technicians, supervising scientists, the laboratory manager, clinicians, patients, ethics committee members, suppliers and regulators. Each risk has one owner role, and the laboratory manager keeps the register current and reports to the quality committee each quarter.

Risk matrix: before and after controls

Each cell shows hazard numbers placed by likelihood and impact. Compare the two grids to see how controls move each hazard.

Before controls

Inherent risk

Risk before controls: rows are likelihood from almost certain to rare, columns are impact from insignificant to catastrophic. Cells list hazard numbers.
1
Insignificant		 2
Minor		 3
Moderate		 4
Major		 5
Catastrophic
5 Almost certain
4 Likely Likelihood 4, impact 3, score 12, high: H03 H07 Likelihood 4, impact 5, score 20, critical: H01
3 Possible Likelihood 3, impact 3, score 9, medium: H05 Likelihood 3, impact 4, score 12, high: H02 Likelihood 3, impact 5, score 15, high: H04
2 Unlikely Likelihood 2, impact 4, score 8, medium: H06 Likelihood 2, impact 5, score 10, high: H08
1 Rare

After controls

Residual risk

Risk after controls: rows are likelihood from almost certain to rare, columns are impact from insignificant to catastrophic. Cells list hazard numbers.
1
Insignificant		 2
Minor		 3
Moderate		 4
Major		 5
Catastrophic
5 Almost certain
4 Likely
3 Possible
2 Unlikely Likelihood 2, impact 2, score 4, low: H05 Likelihood 2, impact 3, score 6, medium: H02 H03 H07 Likelihood 2, impact 4, score 8, medium: H01 H04
1 Rare Likelihood 1, impact 4, score 4, low: H06 Likelihood 1, impact 5, score 5, medium: H08
  • Low 1 to 4
  • Medium 5 to 9
  • High 10 to 16
  • Critical 17 to 25

Hazard register

A summary first, then the detail for each hazard.

Summary of hazards with scores before and after controls
No.HazardBeforeAfterOwner
H01 Specimen mislabeling and misidentification 20 Critical 8 Medium Laboratory manager
H02 Analytical error from calibration drift and bias 12 High 6 Medium Supervising scientist
H03 Instrument or data pipeline failure 12 High 6 Medium IT lead
H04 Unauthorized access to patient results and consent gaps 15 High 8 Medium Data protection lead
H05 Keeping samples and data longer than approved 9 Medium 4 Low Data protection lead
H06 Misuse of licensed reference data 8 Medium 4 Low Procurement and contracts lead
H07 Irreproducible results and sampling bias in studies 12 High 6 Medium Research lead
H08 Biological exposure during specimen handling 10 High 5 Medium Health and safety lead
H01

Specimen mislabeling and misidentification

Safety Before 20 After 8

A specimen is labeled with the wrong patient identifier, placed in the wrong tube or logged against the wrong request, so a result is released for the wrong person or is missing when it is needed.

Who or what is affected: Patients, clinicians and laboratory staff

Causes

Busy periods, handwritten labels and unclear referral forms from outside sites.

Consequences

Wrong treatment decisions, repeat sampling, patient harm and legal exposure.

Existing controls

  • Barcode labels are printed at registration for each specimen.
  • Technicians check the name and date of birth against the request form.

Control gaps

Manual entry is used when scanners fail, and the second check is skipped during peaks.

Additional controls

  • Prevent: Require a second identifier check at receipt, aliquoting and release with the scan recorded.
  • Detect: Review weekly reports of rejected, unmatched and corrected specimen records.
Likelihood 4 x impact 5 before; 2 x 4 after Owner: Laboratory manager Target: Within 30 days Early warning: Specimens with an identifier mismatch or missing second check at receipt or release.
H02

Analytical error from calibration drift and bias

Operational Before 12 After 6

An analyser drifts out of calibration or a method has a hidden bias, so results are consistently high or low and the error goes unnoticed until a clinician questions a value.

Who or what is affected: Patients, clinicians and research users

Causes

Reagent lot changes, temperature shifts, ageing components and reliance on a single control level.

Consequences

Misdiagnosis risk, wrong monitoring decisions, repeat testing and loss of trust.

Existing controls

  • Daily quality control material is run at two levels.
  • Calibration is performed by the instrument supplier at set intervals.

Control gaps

Quality control rules are applied by eye, and bias trends across months are not plotted.

Additional controls

  • Prevent: Validate every method change and check bias against a reference method before routine use.
  • Respond: Hold results from the affected run, repeat testing and inform clinicians of corrected values.
Likelihood 3 x impact 4 before; 2 x 3 after Owner: Supervising scientist Target: Within 45 days Early warning: Quality control results outside agreed limits or analyser calibration overdue.
H03

Instrument or data pipeline failure

Technology and data Before 12 After 6

An analyser, network link or data feed to the laboratory information system fails in the middle of a run, so samples are delayed, results are lost or partial results are sent to clinicians.

Who or what is affected: Clinical teams, patients waiting for results and IT staff

Causes

Power loss, software updates, cable faults and interface changes made without testing.

Consequences

Delayed results, lost or duplicated messages, urgent samples sent elsewhere and clinical risk.

Existing controls

  • Analysers are serviced under a written maintenance schedule.
  • Results are stored locally until the link to the system is restored.

Control gaps

Interface messages are not checked for completeness after an outage, and the backup analyser is rarely tested.

Additional controls

  • Prevent: Keep a tested backup analyser and a documented change process for software and interface updates.
  • Recover: Run a recovery drill each quarter that restores interface queues and checks for lost messages.
Likelihood 4 x impact 3 before; 2 x 3 after Owner: IT lead Target: Within 60 days Early warning: Interface queue backlog above the agreed level or a repeated analyser error code.
H04

Unauthorized access to patient results and consent gaps

Legal and compliance Before 15 After 8

Patient results or personal details are viewed, printed or sent to someone without a right to see them, or residual samples are used without the consent the patient gave, which breaks privacy and trust.

Who or what is affected: Patients, families and referring clinicians

Causes

Shared logins, staff curiosity, unclear consent wording on request forms and fax or email errors.

Consequences

Complaints, legal action, loss of patient trust and disciplinary action.

Existing controls

  • Staff sign confidentiality agreements when they join.
  • Printed reports are collected only by authorized couriers.

Control gaps

Consent status is not checked before residual samples are used in studies.

Additional controls

  • Prevent: Restrict record access by role and require a reason for opening a record outside the patient list.
  • Detect: Review access logs each month and flag views of records with no clinical link.
Likelihood 3 x impact 5 before; 2 x 4 after Owner: Data protection lead Target: Within 30 days Early warning: Repeated record views with no clinical reason or reports sent to an unverified address.
H05

Keeping samples and data longer than approved

Legal and compliance Before 9 After 4

Residual specimens, images and records are kept beyond the approved period or deleted too early, or deletion leaves copies on backup media and local drives, so data is exposed and legal duties are not met.

Who or what is affected: Patients, research partners and staff

Causes

Unclear ownership, freezer clutter, retention rules that differ between record types and manual deletion.

Consequences

Unlawful storage, exposure in a breach, failed audits and weakened consent.

Existing controls

  • A retention schedule is listed in the quality manual.
  • Freezer inventories are reviewed when space runs short.

Control gaps

Backup copies are not included in deletion checks, and no one owns old freezer boxes.

Additional controls

  • Prevent: Attach a retention date and owner to every stored sample and dataset at the point of storage.
  • Respond: Quarantine records found beyond their date and confirm deletion in writing, including backup copies.
Likelihood 3 x impact 3 before; 2 x 2 after Owner: Data protection lead Target: Within 60 days Early warning: Samples or datasets held beyond the approved retention period without a recorded approval.
H06

Misuse of licensed reference data

Supplier Before 8 After 4

Reference ranges, coded test catalogues or external datasets are copied into reports, shared outside their licence or used after the licence has ended, which can break contract terms and create legal claims.

Who or what is affected: Laboratory staff, licence holders and clinicians using reports

Causes

Unclear licence terms, staff copying content into new templates and renewals that lapse unnoticed.

Consequences

Contract breach, withdrawal of data, costly claims and a gap in clinical reference material.

Existing controls

  • Supplier contracts list the permitted uses for reference data.
  • The licence holder is named in the quality manual.

Control gaps

Licence end dates are not tracked, and new staff are not told the limits on sharing.

Additional controls

  • Prevent: Keep a register of every licensed dataset with its permitted use, end date and named licence holder.
  • Detect: Check quarterly that report templates and shared files use only licensed content.
Likelihood 2 x impact 4 before; 1 x 4 after Owner: Procurement and contracts lead Target: Within 60 days Early warning: A licence due to end within 60 days with no renewal in progress.
H07

Irreproducible results and sampling bias in studies

Operational Before 12 After 6

Study samples are chosen from a narrow or convenient group, methods are not written down in enough detail, or results cannot be repeated, so findings are misleading and decisions based on them are weak.

Who or what is affected: Research partners, future patients and the public

Causes

Convenience sampling, incomplete method notes, pressure to publish and changes made mid-study.

Consequences

Misleading findings, wasted resources, withdrawn papers and harm to future patients.

Existing controls

  • Study protocols are written before data collection begins.
  • Results are reviewed by a second scientist before they are reported.

Control gaps

Protocol changes are not logged, and repeat testing is rare once results look satisfactory.

Additional controls

  • Prevent: Require a written sampling plan and an ethics approval reference before any residual material is used.
  • Respond: Repeat a sample of analyses on retained material and report any differences openly.
Likelihood 4 x impact 3 before; 2 x 3 after Owner: Research lead Target: Within 90 days Early warning: Protocol amendments made without a logged reason or ethics approval reference.
H08

Biological exposure during specimen handling

Safety Before 10 After 5

A technician is cut, splashed or exposed to aerosols while opening tubes, centrifuging or handling sharps, which can transmit infection to the worker and to colleagues.

Who or what is affected: Laboratory technicians, cleaners and visiting staff

Causes

Rushed work, damaged containers, broken centrifuge tubes and gaps in training.

Consequences

Infection of staff, sickness absence, breached legal duties and loss of confidence.

Existing controls

  • Staff wear gloves, gowns and eye protection at the bench.
  • Sharps are placed in puncture resistant containers at the bench.

Control gaps

Cabinet checks are not recorded, and new staff start bench work before training is signed off.

Additional controls

  • Prevent: Use closed tube systems and biological safety cabinets for open steps, with a written procedure for each.
  • Respond: Provide post exposure reporting, prompt occupational health referral and an incident log review.
Likelihood 2 x impact 5 before; 1 x 5 after Owner: Health and safety lead Target: Within 30 days Early warning: Near misses or sharps injuries reported in the same area over a rolling four week period.

Rating method and evaluation

Each risk is rated on two five-point scales. Likelihood runs from Rare to Almost certain, and impact runs from Insignificant to Catastrophic, covering harm to patients and staff, effect on results, legal exposure, cost and loss of trust. Multiplying the two gives a score from 1 to 25, placed in one of four bands: Low from 1 to 4, Medium from 5 to 9, High from 10 to 16 and Critical from 17 to 25. Inherent risk is the score before any controls. Residual risk is the score after existing and additional controls are in place, and it must never be higher than the inherent score. Where inherent risk is 10 or more, the residual score must be lower. Critical risks need immediate action and a named senior owner. High risks need a dated plan reviewed by the quality committee. Medium risks need routine controls with a named owner, and Low risks are accepted and watched. Scores are challenged by the technicians who do the work, by a second scientist who was not involved in scoring, and by the quality lead, and any rating is reviewed whenever a warning indicator reaches its threshold or an incident occurs.

Likelihood, impact and rating bands

Likelihood

  • 5 Almost certain: Expected to happen in most circumstances.
  • 4 Likely: Will probably happen in many circumstances.
  • 3 Possible: Could happen at some time.
  • 2 Unlikely: Not expected, but it could happen.
  • 1 Rare: Only in exceptional circumstances.

Impact

  • 1 Insignificant: No lasting effect. Handled within routine work.
  • 2 Minor: Small effect that is quickly corrected.
  • 3 Moderate: Noticeable effect that needs managed effort to correct.
  • 4 Major: Serious effect on people, delivery or reputation.
  • 5 Catastrophic: Severe or lasting effect that threatens the whole activity.

Bands (likelihood x impact)

  • Low (1 to 4): Accept and monitor.
  • Medium (5 to 9): Manage with routine controls.
  • High (10 to 16): Senior attention and a treatment plan.
  • Critical (17 to 25): Act first. Do not proceed until reduced.

Monitoring, escalation and review

Review this assessment every 6 months, and sooner when an indicator below reaches its threshold.

Early-warning indicators and escalation thresholds
Indicator to watchEscalate when
Specimens with an identifier mismatch or missing second check at receipt or release.Escalate to the supervising scientist at once for any mismatch, and to the laboratory manager if more than two occur in a week.
Quality control results outside agreed limits or analyser calibration overdue.Hold affected results and escalate to the supervising scientist immediately, and to the laboratory manager if the instrument stays out of limits for a day.
Failed logins, unexplained record access or unreviewed access rights for staff.Escalate to the IT lead within one working day, and to the data protection lead if personal data may have been seen by an unauthorized person.
Residual samples or datasets held beyond the approved retention period without a recorded approval.Escalate to the data protection lead when found, and quarantine the material until a decision is recorded.
Reference datasets used without a current licence check or research use without ethics approval.Stop the use and escalate to the quality lead within two working days, and to the ethics committee contact if research was involved.

Contingency arrangements

If a serious event occurs, such as a mislabeled specimen released to a clinician, a confirmed data breach or an analyser failure during a busy period, the supervising scientist stops affected release, quarantines the batch and informs the laboratory manager. Clinicians are told quickly and clearly about any result that may be wrong, and patients are contacted through the clinical team. The IT lead isolates the affected system and restores data from the latest tested backup. Patient samples are moved to a validated backup analyser or a partner laboratory under an agreed contract. Privacy and regulatory contacts are made through the quality lead as the relevant rules require.

Prioritized action plan

  1. Introduce a second identifier check at receipt, aliquot and release, owner laboratory manager, within 30 days.
  2. Lock analyser calibration and quality control records to a dated review, owner supervising scientist, within 45 days.
  3. Enable multi-factor sign in and restrict record access by role, owner IT lead, within 30 days.
  4. Set a retention and deletion schedule for samples and data, owner data protection lead, within 60 days.
  5. Require ethics approval and written licence checks before any residual sample or reference dataset is used, owner quality lead, within 60 days.

Conclusion

Reliable laboratory work depends on steady habits: two identifier checks at every step, validated and calibrated instruments, clear data ownership, careful limits on use of residual samples and written review of every method change. The highest scores sit with specimen identification, instrument drift and privacy, and each has actions that bring the residual score down. Treat the register as a living record, review it on the stated cycle, and seek qualified advice for any real clinical, privacy, research or legal question.

Assumptions and limitations

Assumptions

  • The laboratory serves patients and referrers and keeps records in an electronic system managed by a central team.
  • Staff are trained technicians who work under a supervising scientist and follow written procedures.
  • Jurisdiction is not specified, so privacy and retention duties are described in general terms only.

Limitations

  • The scores are teaching examples and do not describe any real laboratory or service.
  • Health, privacy and research rules differ by place and change over time, so specialist review is needed.
  • This is educational content and does not replace a formal site-specific assessment or licensed professional advice.

Related frameworks to study

  • Hierarchy of controls
  • Failure mode and effects analysis
  • Root cause analysis
  • Three lines model of risk ownership
  • Plan, do, check, act improvement cycle

Healthcare Risk Assessment

China, India, United States, Indonesia, Pakistan, Nigeria, Brazil, Bangladesh, Russia, Japan, Mexico, Philippines, Vietnam, Egypt, Turkey, Germany, United Kingdom, France, Italy, Canada, South Korea, Australia, Spain.

For Learning Reference Only: This assessment demonstrates how risk assessment principles are applied in a practical setting, providing a useful reference for learning and understanding. Actual assessments may be adapted to suit specific site conditions and circumstances.

Keep learning

Study the subject behind this assessment.

Laboratory Technician Operations course Read the best practices for this course

More Healthcare risk assessments

Hourly Active: 45,552 Learners